**RESULTS**

**OBJECTIVE**

- To present results of 2 phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2) and 1 confirmatory trial (INTEGUMENT-3) of roflumilast cream 0.15% in patients aged ≥6 years with mild to moderate atopic dermatitis.

*Purpose of the study:*

Evaluation of the efficacy and safety of roflumilast cream 0.15% in patients aged ≥6 years with mild to moderate atopic dermatitis.

**METHODS**

- Randomized, double-blind, phase 3, placebo-controlled trials in patients aged ≥6 years with mild to moderate atopic dermatitis.

**INTRODUCTION**

- Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor that can modify 

**METHODS**

- Randomized, double-blind, phase 3, placebo-controlled trials in patients aged ≥6 years with mild to moderate atopic dermatitis.

**RESULTS**

- Significant improvement based on 75% improvement in Eczema Area and Severity Index (EASI) score from baseline at Week 4 in INTEGUMENT-1.

**CONCLUSIONS**

- Roflumilast cream 0.15% significantly improved atopic dermatitis and all secondary endpoints.

**REFERENCES**


**DISCLOSURES**

- All authors have no conflicts of interest to disclose.